Autoreactive memory and effector CD4-positive T cell specific for myelin antigens (No standard abbreviation is universally established. Some literature may informally abbreviate as "Myelin-reactive CD4+ T cell" or "CD4+ T_EM cell" (for effector-memory subset))

Autoreactive memory and effector CD4-positive T cells, specifically reactive to central nervous system myelin antigens (such as myelin basic protein, myelin oligodendrocyte glycoprotein), are a functionally defined T lymphocyte population critical for the pathogenesis of autoimmune demyelinating diseases like multiple sclerosis[2][4][3][1]. These cells arise when naïve CD4+ T cells are stimulated by myelin-derived antigens, presented via MHC class II molecules (notably HLA-DR15), and differentiate into various effector T helper phenotypes (especially Th1 and Th17). They migrate into the CNS by crossing the blood–brain barrier, where they release pro-inflammatory cytokines (IFN-γ, IL-17, TNF-α, GM-CSF), drive neuroinflammation, demyelination, and coordinate with B cells and other immune cells to sustain disease activity[5][4][3]. These cells are elucidated as key therapeutic targets for MS due to their pivotal role in disease initiation and propagation, and are monitored as biomarkers for disease state, drug efficacy, and patient selection in immunotherapies[4][2].

Other names

Myelin-specific CD4+ T cellMyelin-autoreactive CD4+ T cellMyelin-reactive Th cellAutoreactive CD4+ T cellMyelin-reactive effector/memory CD4+ T cell

Inhibition of CNS trafficking/migration (natalizumab, fingolimod); Immunomodulation/shifting of T cell phenotype (glatiramer acetate, dimethyl fumarate, interferon-beta); Cytokine pathway blockade (anti-IL-23p19, anti-IL-17, anti-TNF); Cell depletion (alemtuzumab, ocrelizumab for CD20 B cells that aid Th17 cells)